With de­ci­sion loom­ing on J&J, Leg­end's CAR-T, an­a­lyst sees a new cham­pi­on emerg­ing in boom­ing BC­MA space

When the FDA fi­nal­ly makes a de­ci­sion on J&J and Leg­end’s cil­ta-cel — which it’s ex­pect­ed to do by the end of the month — the part­ners may in­stant­ly jump in­to the al­ways pro­lif­er­at­ing BC­MA race. And there’s a good chance the drug will come out on top.

That’s ac­cord­ing to an­a­lyst Kel­ly Shi, whose team over at Jef­feries re­viewed the land­scape on all the CAR-Ts, bis­pecifics and an­ti­body-drug con­ju­gates be­ing aimed at mul­ti­ple myelo­ma and pub­lished a com­pre­hen­sive re­port, com­plete with da­ta charts, on the sta­tus and lat­est clin­i­cal ev­i­dence of about 30 drug can­di­dates.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER